Life Sciences
Neurotechnology company, Grey Matter Neurosciences, announced it secured $14 million in seed financing, which will be used to develop an ultrasound headset for individuals with Alzheimer's disease and test that device in clinical trials.
The company, in partnership with Microsoft, aims to develop cancer medicines, followed by treatments for autoimmune diseases and rare conditions.
DeepScribe will be the first ambient AI partner for Flatiron Health, and will integrate with Flatiron's OncoEMR.
The partnership gives Lantern clients entry into customized substance use disorder treatment and telemedicine services.
The olivia app will allow patients to aggregate their health data in a central location.
The aim of the partnership is to allow healthcare providers to offer precision medicine support tools.
The funds will be used to strengthen the development of its proprietary AI and enhance technology-enabled delivery of clinical trials.
SpaceX's Dragon spacecraft, which recently returned from the ISS, included 50 biotechnology, physical science and student research payloads.
Bernke Papenburg, program manager of Robotics at Rijnstate Hospital in the Netherlands, previews her HIMSS25 talk, where she will discuss the challenges associated with deploying digital technology in a hospital setting.
AMD is making a $20 million equity investment to bolster Absci's drug discovery efforts and expand AMDs accelerators and ROCm software.